Transfusion Medicine Reviews
Volume 21, Issue 4 , Pages 317-336 , October 2007

Cellular Therapies: A Canadian Blood Services Research and Development Symposium

References 

  1. Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol. 1957;3:241–252
  2. Mathe G, Amiel JL, Schwarzenberg L, et al. Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res. 1965;25:1525–1531
  3. Bortin MM, Rimm AA, Saltzstein EC. Graft versus leukemia: Quantification of adoptive immunotherapy in murine leukemia. Science. 1973;179:811–813
  4. Weiden PL, Flournoy N, Sanders JE, et al. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc. 1981;13:248–251
  5. Kirkpatrick CH, Rich RR, Graw RG, et al. Treatment of chronic moniliasis with lymphocyte transfusions. Lancet. 1970;2:569;(letter)
  6. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465
  7. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310–2318
  8. Bar BM, Schattenberg A, Mensink EJ, et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol. 1993;11:513–519
  9. Slavin S, Naparstek E, Nagler E, et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553–1562
  10. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200:1623–1633
  11. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer–resistant fresh solid tumor cells by interleukin 2–activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823–1841
  12. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318–1321
  13. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129
  14. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol. 2001;1:209–229
  15. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte–directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science. 1995;270:475–480
  16. Cairo MS, Wagner JE. Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation. Blood. 1997;90:4665–4678
  17. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non-malignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–1618
  18. Barker JN, Davies SM, DeFor T, et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen–matched unrelated donor bone marrow: Results of a matched-pair analysis. Blood. 2001;97:2957–2961
  19. Eapen M, Rubinstein P, Zhang M-J, et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol. 2006;24:145–151
  20. Majhail NS, Weisdorf DJ, Wagner JE, et al. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood. 2006;107:3804–3807
  21. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105:1343–1347
  22. Verneris MR, Brunstein C, DeFor TE, et al. Risk of relapse (REL) after umbilical cord blood transplantation (UCBT) in patients with acute leukemia: Marked reduction in recipients of two units. Blood. 2005;106:93;(abstr)
  23. Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003;102:1915–1919
  24. Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112–117
  25. Kiessling R, Klein E, Pross H, et al. “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol. 1975;5:117–121
  26. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–1492
  27. Kärre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2–deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675–678
  28. Multhoff G, Botzler C, Jennen L, et al. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol. 1997;158:4341–4350
  29. Krause SW, Gastpar R, Andreesen R, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide–activated, autologous natural killer cells: A clinical phase I trial. Clin Cancer Res. 2004;10:3699–3707
  30. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652–658
  31. Arai S, Kindy K, Swearingen M, et al. Phase I study of adoptive immunotherapy using the cytotoxic natural killer (NK) cell line, NK-92, for treatment of advanced renal cell carcinoma and malignant melanoma. Blood. 2003;16:102;(abstr)
  32. Tonn T, Becker S, Esser R, et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res. 2001;10:535–544
  33. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol. 2006;16:412–418
  34. Yodoi J, Teshigawara K, Nikaido T, et al. TCGF (IL 2)–receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer–like cell line (YT cells). J Immunol. 1985;134:1623–1630
  35. Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gamma-delta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood. 2001;97:708–713
  36. Matsuo Y, Drexler HG. Immunoprofiling of cell lines derived from natural killer–cell and natural killer–like T-cell leukemia-lymphoma. Leuk Res. 2003;27:935–945
  37. Suck G, Branch DR, Smyth MJ, et al. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol. 2005;33:1160–1171
  38. Suck G, Branch DR, Keating A. Irradiated KHYG-1 retains cytotoxicity: Potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol. 2006;82:355–361
  39. Suck G, Branch DR, Aravena P, et al. Constitutively polarized granules prime KHYG-1 NK cells. Int Immunol. 2006;18:1347–1354
  40. Djeu JY, Jiang K, Wei S. A view to a kill: Signals triggering cytotoxicity. Clin Cancer Res. 2002;8:636–640
  41. Leger CS, Nevill TJ. Hematopoietic stem cell transplantation: A primer for the primary care physician. CMAJ. 2004;170:1569–1577
  42. Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol. 2004;11:386–391
  43. Antin JH. Stem cell transplantation-harnessing of graft-versus-malignancy. Curr Opin Hematol. 2003;10:440–444
  44. Baron F, Sandmaier BM. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol. 2005;12:435–443
  45. Schattenberg AV, Dolstra H. Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Curr Opin Oncol. 2005;17:617–621
  46. Branch DR, Gallagher MT, Forman SJ, et al. Endogenous stem cell repopulation resulting in mixed hematopoietic chimerism following total body irradiation and marrow transplantation for acute leukemia. Transplantation. 1982;34:226–228
  47. Drexler C, Wagner T. Blood group chimerism. Curr Opin Hematol. 2006;13:484–489
  48. Moise KJ. Umbilical cord stem cells. Obstet Gynecol. 2005;106:1393–1407
  49. Rogers S, Lowenthal A, Terheggen HG, et al. Induction of arginase activity with the Shope papilloma virus in tissue culture cells from an arginemic patient. J Exp Med. 1973;137:1091–1096
  50. Cline M. Gene therapy: Current status and future directions. Schweiz Med Wochenschr. 1986;116:1459–1464
  51. Shimotohno K, Temin HM. Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell. 1981;26:67–77
  52. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans—Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocyte modified by retroviral gene transduction. N Engl J Med. 1990;323:570–578
  53. Orkin S.H., Motulsky A.G., co-chairs: Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Bethesda, MD, National Institute of Health 1995. Available: http://www4.od.nih.gov/oba/rac/panelrep.pdf
  54. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286:2244–2245
  55. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–672
  56. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–419
  57. Yoshimitsu M, Sato T, Tao K, et al. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A. 2004;101:16909–16914
  58. Huston DP. The biology of the immune system. JAMA. 1997;278:1804–1814
  59. Pandha HS, John RJ, Hutchinson J, et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate–pulsed cells: A phase I/II study. Br J Urol Int. 2004;94:412–418
  60. Barrou B, Benoit G, Ouldkaci M, et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother. 2004;53:453–460
  61. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL response against metastatic prostate tumours. J Clin Invest. 2002;109:409–417
  62. Morse MA, Clay TM, Hobeika AC, et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005;11:3017–3024
  63. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12:878–887
  64. Medin JA, Liang SB, Hou JW, et al. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther. 2005;12:540–551
  65. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–2413
  66. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401–409
  67. Blaese RM, Culver KW, Chang L, et al. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992. Hum Gene Ther. 1993;4:521–527
  68. Marshall E. FDA halts all gene therapy trials at Penn. Science. 2000;287:565–567
  69. Woods NB, Bottero V, Schmidt M, et al. Gene therapy: Therapeutic gene causing lymphoma. Nature. 2006;440:1123;(letter)
  70. Institute of Medicine of the National Academies . Committee on establishing a national cord blood stem cell bank program. In:  Meyer EA,  Hanna K,  Gebbie K editor. Cord blood: Establishing a national hematopoietic stem cell bank program. Washington, DC: The National Academies Press; 2005;Available at http://www.nap.edu/catalog/11269.html

☆ This conference, the fourth annual Canadian Blood Services Research and Development international symposium, took place at the University of Toronto in Toronto, Ontario, Canada, on September 16, 2006, and was chaired by Dr Donald R. Branch, Research and Development Scientist, Canadian Blood Services and Associate Professor of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada.

PII: S0887-7963(07)00046-6

doi: 10.1016/j.tmrv.2007.05.007

Transfusion Medicine Reviews
Volume 21, Issue 4 , Pages 317-336 , October 2007

Article Tools

* Image Usage & Resolution